AstraZeneca (LON:AZN) Earns “Buy” Rating from Citigroup

AstraZeneca (LON:AZNGet Rating)‘s stock had its “buy” rating restated by research analysts at Citigroup in a research note issued to investors on Wednesday, November 16th, reports.

AZN has been the topic of a number of other reports. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 10th. JPMorgan Chase & Co. set a £125 ($147.81) price objective on shares of AstraZeneca in a report on Thursday, November 10th. Barclays reaffirmed an “overweight” rating and issued a £125 ($147.81) price objective on shares of AstraZeneca in a research report on Friday, November 11th. UBS Group set a £101 ($119.43) price objective on shares of AstraZeneca in a research report on Thursday, November 10th. Finally, Berenberg Bank decreased their price target on shares of AstraZeneca from £120 ($141.89) to £118 ($139.53) and set a “buy” rating for the company in a research report on Wednesday, October 19th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to, AstraZeneca has a consensus rating of “Moderate Buy” and an average price target of £111.65 ($132.02).

AstraZeneca Stock Performance

AZN stock traded up GBX 96 ($1.14) on Wednesday, hitting £110.50 ($130.66). The company’s stock had a trading volume of 950,799 shares, compared to its average volume of 2,060,204. The company has a current ratio of 0.81, a quick ratio of 0.59 and a debt-to-equity ratio of 88.97. The stock has a market cap of £171.22 billion and a price-to-earnings ratio of 10,424.53. The firm has a 50 day moving average of £102.59 and a two-hundred day moving average of £105.09. AstraZeneca has a 1 year low of GBX 8,090.32 ($95.66) and a 1 year high of £115.40 ($136.46).

AstraZeneca Company Profile

(Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Featured Stories

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.